Target- |
MechanismT lymphocytes stimulants |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomised, Double-blind Placebo-controlled Study to Assess the Safety of Four Single Ascending Doses of HF1020 in Healthy Male Subjects
The study aims to:
study the safety of the drug (HF1020) in healthy male adults
study how well the study drug (HF1020) is tolerated in healthy male adults
find the maximum dose that is tolerated in healthy male adults
100 Clinical Results associated with Trident Pharmaceuticals, Inc.
0 Patents (Medical) associated with Trident Pharmaceuticals, Inc.
100 Deals associated with Trident Pharmaceuticals, Inc.
100 Translational Medicine associated with Trident Pharmaceuticals, Inc.